The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

FibroGen today announced the sale of its China subsidiary to UK pharma major AstraZeneca for around $160 million, with the ...

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...